Sugi Predict

Sugi Predict / Compounds / SCHEMBL853499

SCHEMBL853499

SCHEMBL853499

COC(=O)CC1CCNC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A1 P30531 2/20 0.60
▸ GABRA5 P31644 2/20 0.60
▸ GABRB2 P47870 2/20 0.60
▸ SLC6A12 P48065 2/20 0.60
▸ SLC6A11 P48066 2/20 0.60
▸ SLC6A13 Q9NSD5 2/20 0.60
▸ GABRA1 P14867 1/20 0.60
▸ GABRR1 P24046 1/20 0.60
▸ GABRA4 P48169 1/20 0.60
▸ BRD4 O60885 1/20 0.41
▸ EPHX1 P07099 2/20 0.39
▸ ALOX15 P16050 2/20 0.37
▸ CHRM3 P20309 2/20 0.36
▸ GNAI3 P08754 1/20 0.35
▸ GNAO1 P09471 1/20 0.35
▸ GNAI1 P63096 1/20 0.35
▸ TSHR P16473 2/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12571551 1.00 SLC6A1 (0.60) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL12571547 1.00 SLC6A1 (0.60) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Hydrochloric Acid SCHEMBL1966820 0.98 SLC6A1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Hydrochloric Acid SCHEMBL1970167 0.98 SLC6A1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Hydrochloric Acid SCHEMBL1966822 0.98 SLC6A1 (0.58) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Acetic Acid SCHEMBL7163631 0.95 SLC6A1 (0.59) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1038236 0.89 EPHX1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL15550509 0.89 EPHX1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
SCHEMBL1971228 0.89 EPHX1 (0.50) SLC6A1GABRA5GABRB2SLC6A12SLC6A11
Trifluoroacetic Acid SCHEMBL31173504 0.89 SLC6A1 (0.53) SLC6A1GABRA5GABRB2SLC6A12SLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof HAIHE BIOPHARMA CO., LTD. (CN) 2024-11-21 — — US disclosed
EP-4400493-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2024-07-17 — — EP disclosed
CN-114591318-B Pyrazolo heterocyclic compound, preparation method thereof, pharmaceutical composition and application 中国医学科学院药物研究所 2024-06-21 — — CN disclosed
CN-114507243-B Isothiazolo heterocyclic compounds, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-05-14 — — CN disclosed
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 — — US disclosed
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 — — US disclosed
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 — — US disclosed
EP-4269404-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-11-01 — — EP disclosed
CN-116635377-A Ketohexokinase inhibitors and uses thereof 四川海思科制药有限公司 2023-08-22 — — CN disclosed
US-5721254-A ANTIINFLAMMATORY AGENTS; ANALGESICS NOVO NORDISK A/S (DK) 1998-02-24 — — US disclosed
US-5712292-A N-substituted azaheterocyclic carboxylic acids and esters thereof NOVO NORDISK A/S (DK) 1998-01-27 — — US disclosed
US-5693649-A ADMINISTERING TO TREAT NEUROGENIC INFLAMMATION, MIGRAINE OR DIABETIC NEUROPATHY NOVO NORDISK A/S (DK) 1997-12-02 — — US disclosed
US-5688788-A ANTIINFLAMMATORY, ANALGESIC NOVO NORDISK A/S (DK) 1997-11-18 — — US disclosed
US-5668129-A ANTIINFLAMMATORY AGENTS, ANALGESICS OR ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 1997-09-16 — — US disclosed
WO-1997022338-A1 NOVEL METHOD NOVO NORDISK A/S (DK) 1997-06-26 — — WO disclosed
US-5595989-A ANTIINFLAMMATORY AGENTS AND ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 1997-01-21 — — US disclosed
EP-0738262-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1996-10-23 — — EP disclosed
WO-1995018793-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1995-07-13 — — WO disclosed
US-4514414-A NEUROLEPTIC AGENTS SMITHKLINE BECKMAN CORPORATION (US) 1985-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383893-A1 Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof ENPP1, ENPP2, ENPP3 SLC6A1 2245/4885GABRA5 2268/4885GABRB2 1926/4885
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF KHK, GCK, HK1 SLC6A1 921/4885GABRA5 3040/4885GABRB2 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.